Mateon Therapeutics

Mateon is a biopharmaceutical company, develops anti-vascular therapeutics for patients with cancer and sight-threatening eye diseases.

Mateon Therapeutics, Inc. (formerly OXiGENE, Inc.) is a biopharmaceutical company seeking to realize the full potential of vascular targeted therapy (VTT) in orphan oncology indications. VTT includes vascular disrupting agents (VDAs) such as the investigational drugs that Mateon is developing, and anti-angiogenic agents (AAs), a number of which are FDA-approved and widely used in cancer treatment. These two approaches have distinct yet complementary mechanisms of action.